Evidence map›Paper›PMID 42092921›Full record

ReviewMolecular cancer2026

Testosterone and cancers: biological functions, molecular mechanisms and therapy.

Zhixiang Zhou, Tengda Huang, Jiaxin Li, Li Fu, Lin Xu, Xuping Feng, Zheng Zhang, Hongyuan Pan, Ke Qin, Xinyi Zhou and 2 more

Abstract readReview
In one paragraph

Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhixiang Zhou *Department of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Tengda Huang *Department of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Jiaxin Li *Department of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Li FuDepartment of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Lin XuDepartment of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xuping FengDepartment of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Zheng ZhangDepartment of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Hongyuan PanDepartment of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Ke QinDepartment of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xinyi ZhouDepartment of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yan XiangDepartment of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Kefei YuanDepartment of General Surgery and Laboratory of Liver Surgery, Division of Liver Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. ykf13@163.com.

Funding

1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University ZYGD22006Guizhou Provincial Health Commission Science and Technology Fund Project gzwkj2025-300National Natural Science Foundation of China 82472700, 82472745, 82472365, 82373400, 82372660, 82272685, 82202260 and 82173248Scientific and Technological Innovation Ability Enhancement Project for Junior Faculties of Sichuan University 2024SCUQJTX043Sichuan Provincial Science and Technology Support Program 2024NSFSC1894the Project funded by China Postdoctoral Science Foundation 2022TQ0221the Sichuan University postdoctoral interdisciplinary Innovation Fund 10822041A2103
6 · The paper itself

Abstract

Testosterone, the principal androgen in humans, plays an essential role in maintaining physiological homeostasis. In recent years, accumulating evidence has implicated testosterone in the progression of diverse malignancies, underscoring its context-dependent roles in tumor biology. A series of studies suggest that testosterone can act through canonical androgen receptor (AR) signaling as well as non-canonical, AR-related mechanisms to modulate membrane receptor-mediated signal transduction, metabolic reprogramming, and the tumor immune microenvironment, thereby fostering tumor growth, metastasis, maintenance of stemness, and the development of therapy resistance. Notably, interventional strategies targeting testosterone/androgen signaling have entered clinical investigation and have demonstrated therapeutic promise. Beyond the best-developed clinical paradigms of prostate and breast cancer, we also highlight hepatocellular carcinoma and cutaneous melanoma as informative additional contexts that broaden the understanding of testosterone biology across cancers. Here, we propose that testosterone is best understood not simply as a hormonal input into isolated cancer pathways, but as a systems-level endocrine regulator of tumor plasticity that integrates transcriptional programs, rapid kinase signaling, and membrane receptor-associated responses across distinct tumor contexts. Within this framework, membrane androgen signaling is considered an emerging but still largely preclinical therapeutic vulnerability, whereas androgen-directed interventions in prostate and breast cancer represent the most clinically mature translational paradigms.

Indexed as

NeoplasmsTestosteroneAndrogensAnimalsHumansReceptors, AndrogenSignal TransductionTumor MicroenvironmentAndrogensReceptors, AndrogenTestosteroneAndrogen ReceptorCancer TherapyOncogenic PathwayTestosteroneTumor Microenvironment

Identifiers

PMID42092921
PMCPMC13317344

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.